The Assessment of Health Related Quality of Life for Patients with Breast Cancer in dr. M. Djamil Hospital Padang, Indonesia

  • Dian Ayu Juwita Fakultas Farmasi Universitas Andalas
  • Almahdy Almahdy Fakultas Farmasi Universitas Andalas
  • Rizka Afdila Fakultas Farmasi Universitas Andalas
DOI: https://doi.org/10.35814/jifi.v17i1.682

Abstract

Health related quality of life is a feeling of comfort and patient satisfaction with the function of controlling diseases including psychological, social, and physical health. Measurement of quality of life needs to be done because therapeutic interventions such as drugs potentialy to increase or decrease the quality of life. The purpose of this study to determine the effect of chemotherapy on the quality of life of breast cancer patients in Dr. M. Djamil Hospital Padang. Assessment of the quality of life of breast cancer patients was performed using an EORTC QLC-30 questionnaire. The sample of the study was breast cancer patients in surgical polyclinic of Dr. M. Djamil Hospital Padang during the period of March to May 2018 meeting the inclusion criteria. The data is rated in the range 0-100 using a linear transformation formula, then presented as a mean value. The quality of life of breast cancer patients based on the functional scale group of cognitive function domain (71,09 ± 21,05), role function (66,65 ± 26,52), physical function (61,97 ± 22,22), emotional function 60,91 ± 18,24), and social function (51,47 ± 15,24), whereas in symptom scale group from diarrhea domain (24,41 ± 23,69), constipation (26,38 ± 29,36) , dyspnea (31.35 ± 31.80), insomnia (42.24 ± 34.26), financial difficulties (48.03 ± 22.24), decreased appetite (53.00 ± 26.28), pain ( 55,41 ± 20,11), fatigue (58,59 ± 17,58), and nausea and vomiting (68,00 ± 28,82), last for general health status / QoL obtained 65,03 ± 14,83.

References

1. Kementrian Kesehatan RI. Pusat Data dan Informasi (InfoDATIN) Kementrian Kesehatan RI. Jakarta Selatan: Kemenkes RI; 2015.

2. Tunas IK, Sagung CY, Putu AI, Rini N, Nyoman DB. Penilaian Kualitas Hidup Pasien Kanker Serviks dengan Kemoterapi Paklitaksel–Karboplatin di RSUP Sanglah. Jurnal Farmasi Klinik Indonesia. 2016;5(1):35-46.

3. Eiriksson L, Gennady M, Allan C. Neoadjuvan chemoterapy in the treatment of cervical cancer. Canada: Intercophen; 2012.

4. Wang, Huali, Zhu L, Zu H, Yu Y, Yang Y. Clinicopathological risk factors for recurrence after neoadjuvant chemotherapy and radical hysterectomy in cervical cancer. World J Surgical Oncol. 2013;11(301):1–5. doi: 10.1186/1477- 7819-11-301.

5. Dehkordi A, Heydarnejad MS, Fateh D. Quality of life in cancer patients undergoing chemotherapy. Oman Medical Journal. 2009; 24(3): 204 – 207.

6. Perwitasari DA, Jarir A, Iwan D, Mohammad H, Hans G, Hein P, Johan WR, Henk-Jan G. Translation and validation of EORTC QLQ-C30 into Indonesian version for cancer patients in Indonesia. Japanese Journal of Clinical Oncology. 2011;41(4):519–29. doi: 10.1093/jjco/ hyq243.

7. Suwendar, Achmad F, Tri MA, Herri SS. Evaluasi Kualitas Hidup dengan Kuesioner EQ-5D pada Pasien Kanker Serviks Rawat Inap Sebelum dan Setelah Kemoterapi. Jurnal Farmasi Klinik Indonesia. 2017;6(1):1-10.

8. Marcellusi A, Capone A, Favato G, Mennini FS, Baio G, Haeussler K, et al. Health utilities lost and`risk factors associated with HPV-induced diseases in men and women: the HPV Italian collaborative study group. Clin Ther. 2015;37(1):156–67. doi: 10.1016/j. clinthera.2014.11.002

9. Cardoso F, Bedard PL, Winer EP, Pagani O, Senkus-Konefka E, Fallowfield LJ, Kyriakides LJ, Kyriakides S, Costa A, Cufer T, Albain KS. International guidelines for management of metastatic breast cancer: Combination vs Sequential Single-Agent Chemotherapy. J Natl Cancer Inst. 2009; 101: 1174–1181.

10. Perwitasari DA. Pengukuran kualitas hidup pasien kanker sebelum dan sesudah kemoterapi dengan EORTC QLQ C30 di RSUP Dr.Sardjito Yogyakarta. Majalah Farmasi Indonesia. 2009;20(2):68–72.

11. Chean DC, Zang WK, Lim M, Zulkefle N. Health Related Quality of Life (HRQoL) among breast cancer patients receiving chemotherapy in Hospital Melaka: Single Centre Experience. Asian Pacific Journal of Cancer Prevention. 2016;17(12): 5121–5126.

12. Agustini DD, Surahman E, Abdullah R. Kualitas hidup pasien kanker payudara dengan terapi kombinasi Fluorouracil, Doxorubicin, dan Cyclofosfamide. Jurnal Farmasi Klinik Indonesia. 2015; 4(3): 175-185.

13. Noviyani R, Ketut T, Ayu I, Nyoman GB. Uji Validitas dan Reliabilitas Kuesioner EORTC QLQ C-30 untuk Menilai Kualitas Hidup Pasien Kanker Ginekologi di RSUP Sanglah Denpasar. Jurnal Farmasi Klinik Indonesia. 2016;5(2):106-114.

14. Tan ML, Idris DB, Teo LW, Loh SY, Seow GC, Chia YY, Tin AS. Validation of EORTC QLQ-C30 and QLQ-BR23 questionnaires in the measurement of quality of life of breast cancer patients in Singapore. Asia-Pasific Journal of Oncology Nursing. 2014;1(1):22 – 32.

15. Graelss-Sans A, Serral G, Puigpinos-Riera R. Social inequalities in quality of life in a cohort of women diagnosed with breast cancer in Barecelona (DAMA cohort). Cancer Epidemiology. 2018; 54: 38 – 47.

16. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncolology. 2005; 6; 93-102.

17. Wulandari N, Bahar H, Ismail CS. Gambaran kualitas hidup pada penderita kanker payudara di Rumah Sakit Umum Bahteramas Provinsi Sulawesi Tenggara tahun 2017. Jurnal Ilmiah Mahasiswa Kesehatan Masyarakat. 2017; 2(6).

18. Velikova G, Coens C, Efficace F, Greimel E, Groevold M, Johnson C, et al. A health related quality of life in eortc clinical trials 30 years of progress from methodological developments to making a real impact on oncology practice. EJC Supplements IO. 2012;(1):141–9. doi:10.1016/S1359- 6349(12)70023-X

19. Sanders JB, Loftin A, Seda JS, Ehlenbeck C. Psychosocial distress affecting patients with carcinoma in situ comapred to patients with early invasive breast cancer. Clinical Journal of Oncology Nursing; 2014: 18(6).

20. Likun Z, Xiang J, Yi B, Xin D, Tao ZL. A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemtherapy-induced nausea and vomiting in adults. The Oncologist. 2011; 16: 207 – 216.

21. Hawkins R, S Grunberg. Chemoteraphy-induced nausea and vomitting: challenges and opportunities for improved patients outcomes. Clin J Oncol Nurs. 2009;13(1): 54–64. doi: 10.1188/09.CJON.54-64.

22. Cantarero-Villanueva I, Fernandez-Lao C, Fernandez-De-Las-Penas C, Diaz-Rodriguez L, Sanchez-Cantalejo E, Arroyo-Morales M. Assosiation among musculoskeletal impairments, depression body image and fatigue in breast cancer survivors within the first year after treatment. European Journal of Cancer Care. 2011; 20: 632 – 639.

23. Sampath K, Debjit B, Duraivel S, Umadevi M. Traditional and medicinal uses of banana. IC Journal. 2012;1(3):51– 63.

24. Russo F, Linsalata M, Clemente C. The effects of fluorouracil, epirubicin, and cyclophosphamide (fec60) on the intestinal barrier function and gut peptides in breast cancer patients: an observational study. BMC Cancer. 2013.

25. Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KI, Trudeau ME, Koo J, Hood N. Health-Related Quality of Life and psychososial status in breast cancer prognosis: analysis of multiple variables. Journal of Clinical Oncology. 2014; 22(20): 4184 – 4192.
Published
2019-04-24
How to Cite
JUWITA, Dian Ayu; ALMAHDY, Almahdy; AFDILA, Rizka. The Assessment of Health Related Quality of Life for Patients with Breast Cancer in dr. M. Djamil Hospital Padang, Indonesia. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 17, n. 1, p. 114-119, apr. 2019. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/682>. Date accessed: 19 apr. 2024. doi: https://doi.org/10.35814/jifi.v17i1.682.
Citation Formats
Issue
Vol 17 No 1 (2019): JIFI
Section
Articles

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.